Acetylcysteine
- Generic Name
- Acetylcysteine
- Brand Names
- Acetadote
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9NO3S
- CAS Number
- 616-91-1
- Unique Ingredient Identifier
- WYQ7N0BPYC
- Background
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
- Indication
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
- Associated Conditions
- Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
- Associated Therapies
- Airway secretion clearance therapy
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- Conditions
- Engraft FailureRelapseGVHD
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Universidade Federal do Ceara
- Target Recruit Count
- 219
- Registration Number
- NCT04928495
- Locations
- 🇧🇷
Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-11
- Target Recruit Count
- 118
- Registration Number
- NCT04918719
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
- Conditions
- OCD
- Interventions
- Drug: Placebo tablet 600mg
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Target Recruit Count
- 60
- Registration Number
- NCT04904952
- Locations
- 🇧🇩
Sadia Binte Anwar Sonia, Dhaka, Bangladesh
🇧🇩BSMMU, Dhaka, Bangladesh
Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: Prescribe placebo tablets
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04864496
- Locations
- 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of
N-acetylcysteine for Primary Sjögren's Syndrome
- Conditions
- Sjögren SyndromeSicca Syndrome
- Interventions
- Drug: Placebo syrup
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04793646
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil
🇧🇷Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients
- Conditions
- Corona Virus Disease 19 (Covid19)Corona Virus InfectionSevere Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT04792021
- Locations
- 🇪🇬
Al Assema Hospital, Cairo, Egypt
The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: sodium thiosulfate solution
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 140
- Registration Number
- NCT04764643
- Locations
- 🇨🇳
Xijing Hospital of Digestive Disease, Xi'an, Shaanxi, China
Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Conditions
- Sinusoidal Obstruction Syndrome (SOS)Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Instituto Brasileiro de Controle do Cancer
- Target Recruit Count
- 80
- Registration Number
- NCT04712435
- Locations
- 🇧🇷
Jamilla Neves Cavalcante, Sao Paulo, SP, Brazil
A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.
- Conditions
- Surgery
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 50
- Registration Number
- NCT04562597
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.